Portal de Periódicos da CAPES

Activation of Necroptosis in Multiple Sclerosis

2015; Cell Press; Volume: 10; Issue: 11 Linguagem: Inglês

10.1016/j.celrep.2015.02.051

2639-1856

Dimitry Ofengeim, Yasushi Ito, Ayaz Najafov, Yaoyang Zhang, Bing Shan, Judy Park DeWitt, Juanying Ye, Xumin Zhang, Ansi Chang, Helin Vakifahmetoglu-Norberg, Jiefei Geng, Bénédicte F. Py, Wen Zhou, Palak Amin, Jonilson Berlink Lima, Chunting Qi, Qiang Yu, Bruce D. Trapp, Junying Yuan,

Mitochondrial Function and Pathology

Multiple sclerosis (MS), a common neurodegenerative disease of the CNS, is characterized by the loss of oligodendrocytes and demyelination. Tumor necrosis factor α (TNF-α), a proinflammatory cytokine implicated in MS, can activate necroptosis, a necrotic cell death pathway regulated by RIPK1 and RIPK3 under caspase-8-deficient conditions. Here, we demonstrate defective caspase-8 activation, as well as activation of RIPK1, RIPK3, and MLKL, the hallmark mediators of necroptosis, in the cortical lesions of human MS pathological samples. Furthermore, we show that MS pathological samples are characterized by an increased insoluble proteome in common with other neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease (HD). Finally, we show that necroptosis mediates oligodendrocyte degeneration induced by TNF-α and that inhibition of RIPK1 protects against oligodendrocyte cell death in two animal models of MS and in culture. Our findings demonstrate that necroptosis is involved in MS and suggest that targeting RIPK1 may represent a therapeutic strategy for MS.